CEBPD and invasive ductal breast carcinoma: Of these, we chose the invasive ductal carcinoma cell line BT-549 as our model system, since BT-549 expresses relatively high levels of C/EBPδ and has low sensitivity to panobinostat (Fig 5b), allowing us to effectively test the hypothesis that knocking down C/EBPδ will increase panobinostat sensitivity.